Establishment Labs (NASDAQ:ESTA) had its price objective upped by analysts at BTIG Research to $40.00 in a note issued to investors on Wednesday, November 14th, The Fly reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective would indicate a potential upside of 50.32% from the company’s current price.
A number of other research analysts also recently weighed in on the stock. Cowen started coverage on shares of Establishment Labs in a report on Monday, August 13th. They set an “outperform” rating and a $35.00 price target on the stock. Zacks Investment Research downgraded shares of Establishment Labs from a “hold” rating to a “sell” rating in a report on Monday, October 15th. Finally, Jefferies Financial Group started coverage on shares of Establishment Labs in a report on Monday, August 13th. They set a “buy” rating and a $35.00 price target on the stock.
Shares of Establishment Labs stock traded up $0.14 during midday trading on Wednesday, reaching $26.61. 13,600 shares of the company’s stock traded hands, compared to its average volume of 40,841. The company has a debt-to-equity ratio of 0.28, a quick ratio of 6.02 and a current ratio of 7.06. Establishment Labs has a 52 week low of $20.05 and a 52 week high of $30.70.
Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Tuesday, November 13th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.42. The business had revenue of $16.29 million for the quarter, compared to the consensus estimate of $11.50 million. Establishment Labs had a negative net margin of 31.30% and a negative return on equity of 173.53%. On average, research analysts predict that Establishment Labs will post -1.15 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. FMR LLC acquired a new position in Establishment Labs in the 3rd quarter valued at $15,358,000. Perceptive Advisors LLC acquired a new position in Establishment Labs in the 3rd quarter valued at $15,304,000. BlackRock Inc. acquired a new position in Establishment Labs in the 3rd quarter valued at $5,088,000. JW Asset Management LLC acquired a new position in Establishment Labs in the 3rd quarter valued at $3,856,000. Finally, Redmile Group LLC acquired a new position in Establishment Labs in the 3rd quarter valued at $3,615,000. Institutional investors and hedge funds own 21.84% of the company’s stock.
About Establishment Labs
Establishment Labs Holdings Inc, a medical technology company, designs, develops, manufactures, and markets medical devices for aesthetic plastic surgery, reconstructive plastic surgery, and aesthetic dermatology. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name.
Read More: Trading Penny Stocks
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.